Loading...
0

Cholera Vaccine Market by Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others) and End User (Hospitals & Clinics, Research & Academic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

LI_195177
Pages: 149
Feb 2019 | 920 Views
 
Author(s) : Surabhi Pandey and Tenzin Kunsel
Tables: 68
Charts: 29
 

Cholera Vaccine Market Overview:

The global cholera vaccine market size in 2017 is $ 65 million, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025.

A vaccine is a biological preparation that assists in strengthening the immune system and provides acquired immunity against a specific pathogen. Vaccinations have proved to be one of the best methods to treat infectious diseases by many international organizations such as the World Health Organization (WHO). Cholera is one of the type of infectious disease caused by the bacterium Vibrio cholera. It is associated with the severe diarrhea and the immediate treatment is essential as death is inevitable if the disease is left untreated. Cholera is anticipated to be a global threat to public health especially in regions that lack social development. Thus, cholera vaccine is essential to control cholera. There are two types of cholera vaccine available in the market including inactivated and live oral cholera vaccines, whereas inactivated cholera vaccines are successfully employed globally. These vaccines are mainly taken by travelers and the people who are living in the cholera affected region. In addition, WHO is recommended that cholera vaccine should be taken at least 2 weeks before arrival at the destination and at least 1 week of gap between the doses. Hence, these aforementioned factors helps in increasing the global cholera vaccine market share.

Cholera Vaccine Market
Get more information on this report: Request Sample Pages

The demand for the global cholera vaccine market is increasing due to high prevalence of chronic diseases, lack of proper sanitation & consumption of contaminated food, and growth in awareness about cholera preventive care. In addition, the development of novel approaches for new cholera vaccine and increase in government focus on immunization programs further drive the market growth. However, longer timelines required for cholera vaccine production, risk of adverse effects, high costs associated with the development of vaccines, and the time taken for the regulatory approval is projected to impede growth of the cholera vaccine market. On the contrary, high growth opportunities in untapped markets are expected to provide significant profitable opportunities for the manufacturers in the cholera vaccine industry.

Cholera Vaccine Industry

Get more information on this report: Request Sample Pages

Product segment review:

Based on product, the cholera vaccine market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. The Dukoral segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period, owing to the established stockpile of this oral cholera vaccine by WHO. It is the only vaccine that provides protection against diarrhea caused by heat-labile-toxin-producing E. coli. In addition, growth in the number of travelers to the low- and middle-income countries (LMICs), increases the demand for Dukoral vaccine.

Cholera Vaccine Market Segments

Get more information on this report: Request Sample Pages

End user segment review:

Depending on end user, the cholera vaccine market is categorized into hospitals & clinics, research & academic laboratories, and pharmaceutical & biotechnology companies. The research & academic laboratories segment is projected to exhibit the highest growth during the forecast period. This is attributed to the rise in demand for cholera vaccine across the world. This gives immense opportunities to the researchers to use the existing vaccines and develop new cholera vaccines, which should be more effective and affordable. Thus, helps in increasing the cholera vaccine market size in the near future.

 

Cholera Vaccine Industry

Get more information on this report: Request Sample Pages

Region segment review:

Region wise, the cholera vaccine market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2017, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to the increase in the prevalence of cholera disease and rise in importance of immunization. The market in North America is expected to grow at the highest CAGR during the forecast period. The U.S. market has the highest share of the market in 2017, attributable to the launch of the first and only oral cholera vaccine, Vaxchora, in the U.S. Furthermore, the number of travelers from U.S. to cholera-affected countries is increasing, thereby increasing the demand for immunization.

The report provides a comprehensive analysis of the key players operating in the global cholera vaccine market, namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., Johnson & Johnson (Crucell), and Celldex Therapeutics, Inc. The other players in the value chain include Merck & Co., Inc., GlaxoSmithKline plc., and others.

Key Benefits For Cholera Vaccine Market:

  • is report provides a detailed quantitative analysis of the current cholera vaccine market trends and cholera vaccine market forecast estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
  • An in-depth cholera vaccine market analysis includes analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global cholera vaccine market is provided.
  • Region-wise and country-wise cholera vaccine market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current trends and future market potential from 2018 to 2025 in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the cholera vaccine market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global cholera vaccine market.

Cholera Vaccine Key Market Segments:

By Product

  • Dukoral

  • Shanchol

  • Vaxchora

  • Euvichol & Euvichol-Plus

  • Others

By End User

  • Hospitals & clinics

  • Research & Academic Laboratories

  • Others

By Region

  • North America

    • U.S.

    • Canada

    • Mexico

    • Europe

  • Germany

    • France

    • UK

    • Italy

    • Sweden

    • Rest of Europe

  • Asia-Pacific

    • Australia

    • Japan

    • India

    • Vietnam

    • Rest of Asia-Pacific

  • LAMEA

    • Nigeria

    • Malawi

    • Zambia

    • Rest of LAMEA

 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top Player Positioning, 2017
3.4. Porters five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Lack of proper sanitation and consumption of contaminated food
3.5.1.2. Rise in awareness about cholera preventive care
3.5.1.3. Development of novel approaches for new cholera vaccine

3.5.2. Restraints

3.5.2.1. Risk of adverse effects
3.5.2.2. The time taken for the regulatory approval

3.5.3. Opportunities

3.5.3.1. High growth opportunities in untapped markets

CHAPTER 4: CHOLERA VACCINE MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Dukoral

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Shanchol

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Vaxchora

4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Euvichol & Euvichol-Plus

4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Others

4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: CHOLERA VACCINE MARKET, BY END USER

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospitals & Clinics

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Research & Academic Laboratories

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Others

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: CHOLERA VACCINE MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends and opportunities
6.2.2. North America cholera vaccine market, by country

6.2.2.1. U.S. cholera vaccine market by product
6.2.2.2. U.S. cholera vaccine market by end user
6.2.2.3. Canada cholera vaccine market by product
6.2.2.4. Canada cholera vaccine market by end user
6.2.2.5. Mexico cholera vaccine market by product
6.2.2.6. Mexico cholera vaccine market by end user

6.2.3. North America cholera vaccine market, by product
6.2.4. North America cholera vaccine market, by end user

6.3. Europe

6.3.1. Key market trends and opportunities
6.3.2. Europe cholera vaccine market, by country

6.3.2.1. Germany cholera vaccine market by product
6.3.2.2. Germany cholera vaccine market by end user
6.3.2.3. France cholera vaccine market by product
6.3.2.4. France cholera vaccine market by end user
6.3.2.5. UK cholera vaccine market by product
6.3.2.6. UK cholera vaccine market by end user
6.3.2.7. Italy cholera vaccine market by product
6.3.2.8. Italy cholera vaccine market by end user
6.3.2.9. Sweden cholera vaccine market by product
6.3.2.10. Sweden cholera vaccine market by end user
6.3.2.11. Rest of Europe cholera vaccine market by product
6.3.2.12. Rest of Europe cholera vaccine market by end user

6.3.3. Europe cholera vaccine market, by product
6.3.4. Europe cholera vaccine market, by end user

6.4. Asia-Pacific

6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific cholera vaccine market, by country

6.4.2.1. Australia cholera vaccine market by product
6.4.2.2. Australia cholera vaccine market by end user
6.4.2.3. Japan cholera vaccine market by product
6.4.2.4. Japan cholera vaccine market by end user
6.4.2.5. India cholera vaccine market by product
6.4.2.6. India cholera vaccine market by end user
6.4.2.7. Vietnam cholera vaccine market by product
6.4.2.8. Vietnam cholera vaccine market by end user
6.4.2.9. Rest of Asia-Pacific cholera vaccine market by product
6.4.2.10. Rest of Asia-Pacific cholera vaccine market by end user

6.4.3. Asia-Pacific cholera vaccine market, by product
6.4.4. Asia-Pacific cholera vaccine market, by end user

6.5. LAMEA

6.5.1. Key market trends and opportunities
6.5.2. LAMEA cholera vaccine market, by country

6.5.2.1. Nigeria cholera vaccine market by product
6.5.2.2. Nigeria cholera vaccine market by end user
6.5.2.3. Malawi cholera vaccine market by product
6.5.2.4. Malawi cholera vaccine market by end user
6.5.2.5. Zambia cholera vaccine market by product
6.5.2.6. Zambia cholera vaccine market by end user
6.5.2.7. Rest of LAMEA cholera vaccine market by product
6.5.2.8. Rest of LAMEA cholera vaccine market by end user

6.5.3. LAMEA cholera vaccine market, by product
6.5.4. LAMEA cholera vaccine market, by end user

CHAPTER 7: COMPANY PROFILES

7.1. Astellas Pharma, Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance

7.2. Celldex Therapeutics, Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Business performance
7.2.4. Key strategic moves and developments

7.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance

7.4. Eubiologics Co., Ltd.

7.4.1. Company overview
7.4.2. Company snapshot

7.5. Johnson & Johnson (Crucell)

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance

7.6. Sanofi (Shantha Biotechnics Private Limited)

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance

LIST OF TABLES

TABLE 01. GLOBAL CHOLERA VACCINE MARKET, BY PRODUCT, 20172025 ($MILLION)
TABLE 02. CHOLERA VACCINE MARKET FOR DUKORAL, BY REGION, 20172025 ($MILLION)
TABLE 03. CHOLERA VACCINE MARKET FOR SHANCHOL, BY REGION, 20172025 ($MILLION)
TABLE 04. CHOLERA VACCINE MARKET FOR VAXCHORA, BY REGION, 20172025 ($MILLION)
TABLE 05. CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS BY REGION, 20172025 ($MILLION)
TABLE 06. CHOLERA VACCINE MARKET FOR OTHER PRODUCTES BY REGION, 20172025 ($MILLION)
TABLE 07. GLOBAL CHOLERA VACCINE MARKET, BY END USER, 20172025 ($MILLION)
TABLE 08. CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY REGION, 20172025 ($MILLION)
TABLE 09. CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 20172025 ($MILLION)
TABLE 10. CHOLERA VACCINE MARKET FOR OTHER END USERS, BY REGION, 20172025 ($MILLION)
TABLE 11. GLOBAL CHOLERA VACCINE MARKET REVENUE, BY REGION, 20172025 ($MILLION)
TABLE 12. NORTH AMERICA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 13. U.S. CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 14. U.S. CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 15. CANADA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 16. CANADA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 17. MEXICO CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 18. MEXICO CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 19. NORTH AMERICA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 20. NORTH AMERICA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 21. EUROPE CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 22. GERMANY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 23. GERMANY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 24. FRANCE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 25. FRANCE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 26. UK CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 27. UK CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 28. ITALY CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 29. ITALY CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 30. SWEDEN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 31. SWEDEN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 32. REST OF EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 33. REST OF EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 34. EUROPE CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 35. EUROPE CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 36. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 37. AUSTRALIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 38. AUSTRALIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 39. JAPAN CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 40. JAPAN CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 41. INDIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 42. INDIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 43. VIETNAM CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 44. VIETNAM CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 47. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 48. ASIA-PACIFIC CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 49. LAMEA CHOLERA VACCINE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 50. NIGERIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 51. NIGERIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 52. MALAWI CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 53. MALAWI CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 54. ZAMBIA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 55. ZAMBIA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 56. REST OF LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 57. REST OF LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 58. LAMEA CHOLERA VACCINE MARKET, BY PRODUCT, 2017-2025 ($MILLION)
TABLE 59. LAMEA CHOLERA VACCINE MARKET, BY END USER, 2017-2025 ($MILLION)
TABLE 60. ASTELLAS PHARMA: COMPANY SNAPSHOT
TABLE 61. CELLDEX: COMPANY SNAPSHOT
TABLE 62. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 63. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 64. EUBIOLOGICS: COMPANY SNAPSHOT
TABLE 65. J&J: COMPANY SNAPSHOT
TABLE 66. J&J: OPERATING SEGMENTS
TABLE 67. SANOFI: COMPANY SNAPSHOT
TABLE 68. SANOFI: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 01. CHOLERA VACCINE MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL CHOLERA VACCINE MARKET
FIGURE 03. GLOBAL POWERED SURGICAL INSTRUMENT TOP PLAYER POSITIONING, 2017
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTION
FIGURE 08. HIGH COMPETITIVE RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS, AND OPPORTUNITIES: GLOBAL CHOLERA VACCINE MARKET
FIGURE 10. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR DUKORAL, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR SHANCHOL, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR VAXCHORA, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR EUVICHOL AND EUVICHOL-PLUS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER PRODUCTES, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF CHOLERA VACCINE MARKET FOR OTHER END USERS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 18. ASTELLAS PHARMA: NET SALES, 20162018 ($MILLION)
FIGURE 19. ASTELLAS PHARMA: REVENUE SHARE BY PRODUCT SEGMENT, 2018 (%)
FIGURE 20. ASTELLAS PHARMA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 21. CELLDEX: NET SALES, 20152017 ($MILLION)
FIGURE 22. EMERGENT BIOSOLUTIONS: NET SALES, 20152017 ($MILLION)
FIGURE 23. EMERGENT BIOSOLUTIONS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 24. J&J: NET SALES, 20152017 ($MILLION)
FIGURE 25. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. SANOFI: NET SALES, 20152017 ($MILLION)
FIGURE 28. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 
 

Cholera is a bacterial disease causing severe diarrhea and dehydration, usually spread via contaminated water and food. A cholera vaccine is used to prevent and immunize people from the disease. These vaccines are of two types: killed oral O1 with whole-cell with B subunit and killed oral O1 & O139. This killed vaccine is well tolerated and confers high-level (85 90%) protection for 6 months after the second immunization in all vaccines aged more than 2 years. In addition, after 3 years of immunization, the level of protection is about 50% in vaccines that were 5 years or older at the time of vaccination.

The global cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and rise in the awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players.

Based on product, the market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. The demand for Vaxchora is projected to exhibit the fastest market growth during the forecast period due to its advantages such as single dose immunization and reduced adverse effects.

Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the U.S. Furthermore, the number of travelers to cholera-affected countries is increasing, thereby increasing the demand for immunization.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
Cholera Vaccine Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Cholera Vaccine Market"
Purchase Enquiry